Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2025-12-25 @ 3:20 PM
NCT ID:
NCT02957968
Group ID:
EG001
Title:
Cohort B: HER2-negative Hormone Receptor-positive Tumors
Description:
HER2-negative hormone receptor-positive tumors (Cohort B): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel.
Doxorubicin: 60 mg/m2 once every 2 weeks for 4 cycles.
Cyclophosphamide: cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
Paclitaxel: Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
Decitabine: Given IV
Pembrolizumab: Given IV
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
6
Serious Number At Risk:
18
Other Number Affected:
18
Other Number At Risk:
18
Study:
NCT02957968
Results Section:
NCT02957968
Adverse Events Module:
NCT02957968